Literature DB >> 26083156

Detachable-Tip Microcatheters for Liquid Embolization of Brain Arteriovenous Malformations and Fistulas: A United States Single-Center Experience.

Nabeel A Herial1, Asif A Khan, Gregory T Sherr, Mushtaq H Qureshi, M Fareed K Suri, Adnan I Qureshi.   

Abstract

BACKGROUND: The US Food and Drug Administration recently approved a detachable-tip microcatheter, the Apollo microcatheter (eV3, Inc, Irvine, California), to prevent catheter entrapment during embolization of brain arteriovenous malformations (AVMs) using liquid embolic systems.
OBJECTIVE: To report technical aspects and clinical results of cerebral embolizations with the Apollo microcatheter in 7 embolizations in 3 adult patients.
METHODS: A 62-year-old man presented with an AVM in the parieto-occipital region measuring 3.6 × 1.6 cm with major cortical feeders from the right middle cerebral artery (MCA) and minor contribution from the distal right anterior cerebral artery. Two pedicles originating from the MCA were embolized. A 48-year-old woman presented with a left frontal AVM measuring 3.3 × 1.8 cm with arterial feeders from the left MCA, left middle meningeal artery, and contralateral anterior cerebral artery. Three pedicles originating from the left MCA were embolized. A 76-year-old man presented with an arteriovenous fistula with multiple fistulous connections and feeders from both vertebral and occipital arteries and the left posterior cerebral artery draining into the left transverse, torcula, and left sigmoid sinus. Two major occipital artery feeders were embolized.
RESULTS: Seven Apollo microcatheters were used with the Onyx 18 liquid embolic system. The length of the detachable tip was 15 mm in 2 and 30 mm in 5 embolizations. The mean microcatheter in-position time within the pedicle was 20 minutes. Detachment of tip occurred in 3 instances. No limitations in accessing target arterial feeders and safe tip disengagement were noted despite prolonged injection times.
CONCLUSION: Our initial experience supports the feasibility, safety, and effectiveness of detachable-tip microcatheters in treating brain AVMs and arteriovenous fistulas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26083156     DOI: 10.1227/NEU.0000000000000839

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Endovascular Treatment for Low-Grade (Spetzler-Martin I-II) Brain Arteriovenous Malformations.

Authors:  H Baharvahdat; R Blanc; R Fahed; S Smajda; G Ciccio; J-P Desilles; H Redjem; S Escalard; M Mazighi; D Chauvet; T Robert; P Sasannejad; M Piotin
Journal:  AJNR Am J Neuroradiol       Date:  2019-02-21       Impact factor: 3.825

2.  Safety and Effectiveness of First-line Endovascular Management of Low-Grade Brain Arteriovenous Malformations : Single Center Experience in 145 Patients.

Authors:  Maichael Talaat; Eimad Shotar; Kévin Premat; Anne-Laure Boch; Mariette Delaitre; Pierre-Yves Borius; Aurelien Nouet; Stéphanie Lenck; Atika Talbi; Awad Bessar; Mohammed Taema; Ahmed Bessar; Farouk Hassan; Tamer S Elserafy; Etienne Lefevre; Vincent Degos; Nader Sourour; Frédéric Clarençon
Journal:  Clin Neuroradiol       Date:  2022-05-13       Impact factor: 3.649

3.  Onyx embolization with the Apollo detachable tip microcatheter: A single-center experience.

Authors:  Timothy R Miller; Luciano Giacon; Matthew J Kole; Rong Chen; Gaurav Jindal; Dheeraj Gandhi
Journal:  Interv Neuroradiol       Date:  2018-02-26       Impact factor: 1.610

4.  Study of Vertebral Artery Dissection by Ultrasound Superb Microvascular Imaging Based on Deep Neural Network Model.

Authors:  Yanjuan Wang; Huajie Jiao; Huihui Peng; Jinfang Liu; Liyuan Ma; Jianjun Wang
Journal:  J Healthc Eng       Date:  2022-02-26       Impact factor: 2.682

Review 5.  Glue, Onyx, Squid or PHIL? Liquid Embolic Agents for the Embolization of Cerebral Arteriovenous Malformations and Dural Arteriovenous Fistulas.

Authors:  Dominik F Vollherbst; René Chapot; Martin Bendszus; Markus A Möhlenbruch
Journal:  Clin Neuroradiol       Date:  2021-07-29       Impact factor: 3.649

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.